Evaluation of the Condition of Rheumatoid Arthritis After Treatment

NCT02157012 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-09-21

No results posted yet for this study

Summary

To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients

Conditions

Interventions

DRUG

The effectiveness of Xeljanz in rheumatoid arthritis patients

Sponsors & Collaborators

  • Showa Inan General Hospital

    collaborator OTHER
  • Shinshu University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2022-04-30
Completion
2025-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02157012 on ClinicalTrials.gov